PubMed Health⌕ Search

Biomedical subjects

C C Ting

Publications and source records attributed to C C Ting.

At least 37 records · Page 2Linked to original sources

In vivo antitumor activity of anti-CD3-induced activated killer cells.

This study investigates the potential of the alpha CD3-induced killer cells for use in adoptive immunotherapy of tumor growth. The alpha CD3-induced, activated, killer cells (CD3-AK) were generated in DBA/2 (H-2d) splenocytes by preactivation with alpha CD3 and were then cultured in the presence (CD3-AK [alpha CD3+]) or absence (CD3-AK [alpha CD3-]) of alpha CD3. The conventional lymphokine-activated killer (LAK) cells were induced by culturing DBA/2 splenocytes with purified human recombinant interleukin 2. Testing their in vitro cytotoxicity against syngeneic mastocytoma P815, CD3-AK (alpha CD3+) cells gave the highest levels of cytotoxicity and were 20-fold higher than LAK cells and 200-fold higher than CD3-AK (alpha CD3-) cells. However, the cytotoxic activity of LAK or CD3-AK (alpha CD3-) cells was augmented by preincubating them with alpha CD3 for 3 h; then, the difference in cytotoxic activity was reduced from 20- to 4-fold and from 200- to 2-fold, respectively. The in vivo antitumor activity of these killer cells paralleled the in vitro activity. In tests using tumor neutralization experiments, 80-100% of the mice that were challenged with 1 x 10(2) P815 cells remained tumor free after receiving 5 x 10(6) CD3-AK (alpha CD3+) cells. When the challenge dose increased to 1 x 10(3) and to 1 x 10(4) cells, giving CD3-AK (alpha CD3+) cells slowed down the rate of tumor growth but only 20% of the mice remained tumor free. The untreated LAK cells or CD3-AK (alpha CD3-) cells did not induce any protection. After preincubation with alpha CD3 for 3 h, the CD3-AK (alpha CD3-) cells provided protection in 30% of the challenged mice. The phenotype of effectors for mediating the in vitro and in vivo antitumor activities was found to be Thy1+, CD4-, and CD8+ cells. Flow microfluorometry analysis showed that the higher levels of cytotoxic activity obtained with CD3-AK (alpha CD3+) cells could not be simply explained by the increase of CD8+ cells, and the cytotoxic activity of individual CD3-AK (alpha CD3+) cells appeared to be much higher than that of the LAK cells. After tumor growth was established for 1-2 days, giving CD3-AK (alpha CD3+) cells slowed down the rate of tumor growth, and 20% of the mice remained tumor free. These results indicate that CD3-AK cells may be used in the immunotherapy of tumor growth.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.

The present study has characterized the short term and long term cultured murine-activated killer (AK) cells that are induced by antibody directed against the epsilon-chain of T3 complex. The conventional lymphokine AK (LAK) cells were generated by culturing normal B6 spleen cells with purified human rIL-2. The alpha T3-induced AK cells (T3AK) were induced by culturing normal B6 spleen cells with alpha T3 and were then maintained in culture medium supplemented with human rIL-2 and/or alpha T3. After initial activation with alpha T3, lymphocyte proliferation and generation of cytotoxic effectors (T3AK) were noted, and these events were related to the endogenous production of IL-2 and IL-4. Addition of alpha IL-2 and/or alpha IL-4 suppressed both the proliferative response and the cytotoxic response induced by alpha T3. In comparing the T3AK cells with the conventional LAK cells, there were many similarities as well as some distinct differences. Both cells displayed a similar cytotoxic spectrum against a variety of tumor targets. The T3AK cells usually gave much higher levels of cytotoxic activity against susceptible targets. However, the susceptibility of different tumor targets to conventional LAK cells and T3AK cells varied. The time course for the generation of lytic activity also differed between the conventional LAK and T3AK cells. One distinct difference was their ability to survive in vitro. The conventional LAK cells survived in culture for only 1 wk. The T3AK cells could survive for at least 4 to 5 wk with active growth. The serologic phenotype of the LAK precursors was asialo GM1 (AsGM1+) cells, but the T3AK precursors could be either AsGM1+ or AsGM1-, depending on the target cell. The LAK effectors were both Lyt-2+ and Lyt-2-, but the short-term T3AK effectors were exclusively Lyt-2+. The long term T3AK cells (cultured for more than 2 wk) were found to consist of Lyt-2+ and Lyt-2- cells, and these subsets of T3AK cells showed different target specificities. These findings demonstrate the heterogeneity of LAK and T3AK cells, and this heterogeneous property may contribute to their diversity in specificity against different tumor targets and thus may affect their effectiveness in the immunotherapy of cancer.

Animals↗

Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.

This study showed that a mAb (145-2C11) against the T3 epsilon-chain of the TCR complex augmented the cytotoxic activity of the lymphokine-activated killer (LAK) effectors. The LAK cells were induced by culturing normal spleen cells with purified human rIL-2. Adding alpha T3 at the effector phase of the cytotoxic reactions augmented the LAK-mediated cytotoxicity. The alpha T3-augmented LAK killing was seen only with tumor targets, and there was no increase of killing against Con A-induced lymphoblasts. The augmentation effect was dose dependent on both the amounts of alpha T3 and the number of LAK cells added. A very low concentration of alpha T3 (1/10,000 dilution of culture supernatants) was sufficient to induce alpha T3-augmented LAK-mediated cytotoxicity. Human rIL-2 at 10 to 30 U/ml was sufficient to generate LAK cells for maximal alpha T3 augmentation, whereas 300 to 1000 U/ml of IL-2 were needed to generate maximal LAK activity when tested in the absence of alpha T3. LAK cells generated for longer periods of time showed a progressive increase of alpha T3-augmented cytotoxicity. For some targets, the alpha T3-augmented LAK killing was FcR dependent as evidenced by the ability of alpha FcR mAb 2.4G2 to inhibit, and for others it was not inhibited. The alpha T3-augmented killing did not correlate with the FcR expression on target cells as defined by 2.4G2. The LAK cells were both Lyt-2+ and Lyt-2-, but the LAK cells involved in alpha T3-augmented killing were exclusively Lyt-2+. Preincubation of LAK cells with alpha T3, but not preincubation of targets with alpha T3, resulted in augmented killing suggesting that the alpha T3 effect was unrelated to an antibody-dependent cell-mediated cytotoxicity. Our findings indicate that alpha T3 is a potent reagent to augment the cytotoxic reaction of LAK cells. These results suggested that a relationship might exist between the T3 complex and the cytotoxic activity of a subpopulation of Lyt-2+ LAK cells.

Adjuvants, Immunologic↗

Asialo GM1 as an accessory molecule determining the function and reactivity of cytotoxic T lymphocytes.

The expression and function of asialo-GM1 (AsGM1) in alloreactive cytotoxic T lymphocytes (CTL) was studied. We have shown previously that the cytotoxic reactions mediated by AsGM1+-cloned CTL were blocked by anti-AsGM1 or by purified AsGM1. To further determine the role of AsGM1 in CTL-mediated cytotoxicity, we examined the correlation between this blocking effect and the expression of AsGM1 on effector and target cells. Now we found that the blocking by anti-AsGM1 was largely dependent on the expression of AsGM1 on the effector cells in a dose-dependent fashion. The expression of AsGM1 on target cells had only little effect on the blocking of cytotoxic reactions by anti-AsGM1 or AsGM1. A threefold difference was seen in the blocking of AsGM1+ and AsGM1- targets. The observation was in sharp contrast to the effectors as no blocking was ever seen with AsGM1- CTL. Similar to CTL effectors, we found that the expression of AsGM1 and L3T4 were mutually excluded on mitogen-activated T cells, despite the fact that they could coexpress in resting T cells. The expression of AsGM1 on CTL effectors was associated with the antigen-nonspecific natural killer (NK)-like or lymphokine-activated killer (LAK)-like activity exerted by the alloreactive CTL. All AsGM1+ CTL possessed LAK activity against antigen-unrelated tumor targets, and the AsGM1- CTL only displayed antigen-specific alloreactivity. The LAK activity was associated with the expression of AsGM1 on effectors, and was not related to the AsGM1 expression on target cells. These findings indicate that the AsGM1 expressed on alloreactive CTL may function as an accessory molecule for T-cell receptors in the antigen-specific alloreactive cytotoxicity mediated by AsGM1+ CTL. The expression of AsGM1 may also be related to the activation of an NK-like apparatus in these CTL. Therefore, AsGM1 not only may be involved in cytotoxic reactions mediated by AsGM1+ CTL, it may also modulate the specificity of the CTL cytotoxicity.

Adjuvants, Immunologic↗

Generation of antisuppressor T cells for alloreactive cytotoxic T lymphocytes.

This study demonstrated that antisuppressor T cells (TAS) were generated in allogeneic mixed lymphocyte culture (MLC) when supplemented with a conditioned medium containing T cell differentiation factor (CM-TCDF). CM-TCDF was shown to efficiently restore the alloreactive cytotoxic T lymphocytes (CTL) response in accessory cell-depleted MLC. CM-TCDF could also sustain the growth and cytotoxic activity of bulk-cultured CTL. In contrast, cloned CTL only required interleukin 2 to maintain their growth and cytotoxic activity. These findings suggested that bulk-cultured MLC might contain different populations of immunoregulatory cells in addition to CTL effectors. These immunoregulatory cells provide "on" or "off" signals to turn on or turn off the lytic machinery of CTL. The suppressor T cells (Ts) generated in MLC might provide the "off" signal to CTL that resulted in the termination of their cytotoxic activity after 7 days of culturing. When CM-TCDF was supplemented in MLC, we found that TAS were generated. TAS could efficiently abrogate the suppressor activity of anti-allo-TS, but they had no effect on the anti-self veto cell activity. Both the TAS and TS activities were allospecific. The precursors and effectors of TAS were both found to be L3T4+ cells, whereas the TS effectors were Lyt-2+ cells. Generation of TAS was completely blocked by alpha L3T4 antibody and was partially blocked by alpha Thy-1 antibody. In contrast, alpha Lyt-2 antibody or antibodies against class II major histocompatibility complex framework determinants had no effect on TAS generation. Therefore, TAS were different from L3T4+ T helper cells that were induced in the context of recognizing class II major histocompatibility complex determinants. TAS might represent a separate set of immunoregulatory cells that provide an "off" signal to the TS, which allowed the lytic machinery of the CTL to remain active and, thus, to maintain their cytotoxic activity for a prolonged period of time.

Animals↗

Generation of activated killer cells in tumor-bearing hosts.

Activated killer (AK) cells were generated in spleen-cell cultures derived from tumor-bearing hosts (TS) whereas, under the same conditions, cultured normal spleen cells (NS) gave little cytotoxicity. The AK effectors were primarily Thy1+, AGM1- and Lyt2- and thus were neither classic cytotoxic T lymphocytes (CTL) nor classic NK cells. These AK cells selectively killed tumor targets of different etiologic origins and did not kill concanavalin-A-induced lymphoblasts. The broad target-cell reactivity of these AK cells was also confirmed by cold target-inhibition experiments. Generation of AK cell correlated with interleukin-2 (IL-2) production, and the levels of AK cells generation paralleled those of IL-2 production. Furthermore, the generation of AK cells was blocked by the anti-IL-2 receptor monoclonal antibody (MAb) (alpha IL-2R), indicating that IL-2 was involved, and thus these AK cells were lymphokine-activated killer (LAK) cells. We previously showed that the expression of AGM1 on LAK precursors disappeared when they differentiated into LAK effectors, indicating that the activated LAK cells lacked AGM1. When examining the serologic phenotype of the LAK precursors in tumor-bearing hosts, we found that they lacked AGM1, which suggested that these LAK precursors were in an "activated" state. These cells were still Thy1-, and were thus different from fully activated LAK effectors which were Thy1+ cells, indicating that the full differentiation of LAK cells in vivo was arrested in the tumor-bearing hosts. We also found that the presence of small amounts of X-irradiated tumor cells prevented the generation of AK cells. These findings suggest that, in the tumor-bearing hosts, the presence of tumor cells triggers the activation of AK precursors; however, the same tumor cells may also be immunosuppressive, which prevents the full differentiation of AK precursors into AK effectors.

Animals↗

Differential expression of asialo GM1 on alloreactive cytotoxic T lymphocytes and lymphokine-activated killer cells.

The present study was undertaken to examine the differential expression of asialo GM1 (AsGM1) on the responding cells and effectors of alloreactive cytotoxic T lymphocytes (CTL) and lymphokine-induced activated killers (LAK). It was found that AsGM1 was expressed on the 3-day-cultured LAK effectors. Its expression gradually disappeared to the extent that AsGM1 became undetectable after 5 to 6 days of culturing. In contrast, AsGM1 was detected on 3-day CTL generated in mixed-lymphocyte cultures (bulk cultures); however, the levels of AsGM1 expression remained the same for at least 7 days. When examining the expression of AsGM1 on the responding cells, the reciprocal results were obtained. AsGM1 was expressed the LAK responders, but we were unable to demonstrate AsGM1 on CTL responders. Depletion of AsGM1+ cells from the responding population reduced subsequent CTL responses; however, CTL responses could be restored by adding conditioned media containing both interleukin 2 (IL-2) and other helper-T-cell factors and could not be restored by purified IL-2 alone adding at comparable doses. Reconstituting the AsGM1-depleted responders with Lyt-2-depleted splenocytes also restored the CTL response. Furthermore, depletion of AsGM1 cells from the responding population did not reduce the precursor frequency of allo-CTL, whereas the precursor frequency of LAK cells was reduced 42-fold. These findings show that the reduction of CTL responses after depletion of AsGM1+ cells was not due to the removal of precursors; instead, the defect appeared to be in the helper population. We further found that the helper defect was not due to impaired IL-2 production, because the endogenous production of IL-2 AsGM1-depleted responders was not reduced. Therefore, AsGM1+ cells may play a role in the helper pathway other than IL-2 production.

Animals↗

Expression and function of asialo GM1 in alloreactive cytotoxic T lymphocytes.

In the present study we examined asialo GM1 (AsGM1) expression and its function in alloreactive cytotoxic T lymphocytes (CTL). We consistently found that the cytotoxic activity of bulk culture-derived allo-CTL was susceptible to the treatment of anti-AsGM1 (alpha AsGM1) plus complement. To further determine whether the expression of AsGM1 was maintained in CTL, we examined cloned T cells. The expression of AsGM1 in the T cell clones was assessed by their susceptibility to lysis by alpha AsGM1 plus complement and the reduction or abrogation of their cytotoxic activity by this treatment. It was found that, with one exception, all Lyt-2+, Thy-1+ CTL clones were AsGM1+ (seven out of eight), independent of their class specificity (class I or class II). In contrast, all Thy-1+, L3T4+ CTL (2) or helper T cell (4) clones AsGM1-. These findings suggested that there was a close association between the expression of AsGM1 and the expression of Lyt-2. The cytotoxic reaction of the anti-class I MHC CTL clones that expressed AsGM1 was blocked by alpha AsGM1 or alpha Lyt-2 antibody. The Lyt-2+, AsGM1+ anti-class II MHC CTL clone-mediated lysis was inhibited by alpha AsGM1. Addition of AsGM1 in micelle form (AsGM1-M) alone also blocked the cytotoxic reactions. Addition of other structurally similar but antigenically different glycolipids or other non-AsGM1-containing liposome preparations did not affect CTL-mediated cytotoxicity. Furthermore, adding both alpha AsGM1 and AsGM1-M together at proper doses inhibited the blocking effect (deblocking) of either alone, and other structurally similar glycolipids did not inhibit the blocking. The deblocking was specific, since AsGM1-M did not affect the blocking by alpha Lyt-2. These findings indicate that not only is AsGM1 expressed in a majority of Lyt-2+ CTL clones, but it may also be involved in the CTL- target interaction to mediate lytic reaction.

Animals↗

Production of T cell differentiation factor in syngeneic lymphocyte macrophage culture for cytotoxic T lymphocyte generation.

This study demonstrated that T cell differentiation factor (TCDF) was produced in syngeneic lymphocyte-macrophage cultures. Conditioned medium containing TCDF and interleukin 2 (IL 2) induced the differentiation of leukoagglutinin (LA)-activated cytotoxic T lymphocyte precursors (CTLp) into cytotoxic T lymphocyte (CTL) effectors. The production of TCDF and IL 2 peaked at day 4 to 5 in cultures containing normal spleen cells, syngeneic peritoneal macrophages, and indomethacin. Macrophages and T cells with Thy-1+, L3T4+, and Lyt-2- phenotype were needed for TCDF production. There was no requirement for xenogeneic serum in the culture medium; thus, TCDF could be produced in a syngeneic system. Recognition of self Ia molecules appeared to be essential for TCDF production, which was completely abolished by the addition of monoclonal anti-Ia antibody. In our experiments, removal of IL 2 from conditioned medium containing TCDF abolished its ability to generate LA-activated CTL. However, the cytotoxic response could be restored by the addition of a small amount (5 U/ml) of purified human recombinant IL 2 (HRIL 2), which alone was unable to generate LA-activated CTL at this dose. The generation of LA-activated CTL by high dose HRIL 2 (greater than 50 U/ml) was likely due to the endogenous production of TCDF. The bulk of TCDF could be separated from IL 2 by gel filtration in a Sephadex G-100 column. The peak of TCDF activity was concentrated at a m.w. of 16K dalton, and there was very little IL 2 activity in these fractions. When added alone to the LA-activated lymphocyte cultures, these active fractions were unable to induce CTL; supplementation of exogenous IL 2 was needed to restore the cytotoxic responses. Our findings indicate that both IL 2 and TCDF, which are needed in CTL generation. are produced in syngeneic cultures in the absence of antigenic or mitogenic stimulation.

Agglutinins↗

Regulation of the cytotoxic activity of alloreactive cytotoxic T lymphocytes by helper cells and lymphokines.

The cytotoxic activity of alloreactive cytotoxic T lymphocytes (CTL) was maintained and augmented by transferring cells from a 5-day mixed lymphocyte culture MLC into a host culture (HC) containing indomethacin, freshly explanted normal spleen cells, and peritoneal cells which were syngeneic to the MLC cells. The MLC cells used in the transfer experiments were generated by culturing untreated H-2b splenic responders with irradiated H-2d stimulators, or were generated by culturing Lyt-2-depleted H-2b splenic responders with irradiated H-2d stimulators. The allo-CTL were found to be derived from the donor MLC (first culture) when unfractionated MLC cells were transferred into a host (second) culture and incubated for 5 days. In contrast, the allo-CTL were derived from host culture cells when Lyt-2-depleted MLC cells were transferred and the combined cultures incubated for 5 days. In the former case, the augmentation of MLC-derived cytotoxicity did not result from nonspecific expansion of all donor T cells; instead it was mediated by lymphokine(s), distinct from IL-2, produced by helper T cells generated in host culture, which appeared to selectively expand the antigen-specific CTL or to increase the cytotoxic activity of these CTL. The helper T cells were Thy-1+, L3T4+, and Lyt-2-. These findings indicate that antigen-nonspecific help was provided by helper cells or helper factors (lymphokines) generated in the host culture, which maintained and augmented the cytotoxic activity of the fully generated allo-CTL. This helper effect was also seen in the induction of primary allo-CTL responses which could be generated with fewer stimulating cells and with a stronger cytotoxic response at different R/S ratios tested. The generation of allo-CTL in second culture following transfer of Lyt-2-depleted MLC cells to host cultures appears to have involved antigen carryover from the MLC; however, antigen carryover alone was not sufficient. It appears that in the absence of Lyt-2+ suppressor T cells, antigen-specific help might be generated in donor cultures (Lyt-2-depleted MLC) which promoted or recruited the generation of antigen-specific CTL in host culture.

Animals↗

Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells.

In the present study, we have characterized the effectors, precursors, and regulatory ancillary cells involved in the in vitro generation of lymphokine-induced cytotoxicity. It was first shown that at least two lymphokines are needed for the generation of lymphokine-induced cytotoxicity. They are interleukin 2 and a novel lymphokine, the cytotoxic cell differentiation factor (CCDF). CCDF was produced primarily by the macrophages. The effectors of the lymphokine-induced cytotoxic cells thus generated selectively killed tumor targets of different etiological origins. The serological phenotype of lymphokine-induced cytotoxic cell effectors were found to be Thy 1+, Lyt 2-, and AGM1-; therefore, they were neither classic natural killer (NK) cells nor cytotoxic T-lymphocytes. Extensive characterization of the precursors by sequential column separation and antibody lysis and also by limiting dilution analysis showed that they were AGM1+ and Lyt 2-; thus they were NK-like cells. In addition to NK-like cells being identified as the precursors, two other cell compartments were identified as ancillary cells which regulate the lymphokine-induced cytotoxicity. They were the macrophages and T-cells. Macrophages were needed to produce CCDF and to activate the Lyt 1+ helper T-cells to produce interleukin 2. The Lyt 2+ T-cells play a negative role in the regulation of the lymphokine-induced cytotoxic cell response. The process of lymphokine-induced cytotoxicity thus involves a complex interaction between at least two lymphokines (interleukin 2 and CCDF) and three cell compartments, namely, NK-like cells, macrophages, and T-cells of Lyt 1+ and Lyt 2+ phenotypes.

Animals↗

In vitro and in vivo antitumor activity of lymphokine-induced cytotoxic cells.

The present study demonstrates that LICC possess both in vitro and in vivo antitumor activity. The LICC were generated by culturing normal spleen cells with syngeneic peritoneal cells and indomethacin, or with a conditioned medium containing IL 2 with or without a putative new lymphokine, the CCDF. The LICC thus generated selectively killed the lymphoid or solid tumor targets of different H-2 haplotypes and of different etiological origins. The precursors of LICC were probably NK-like cells. The effectors were neither classical NK nor classical cytotoxic T lymphocytes. The LICC were very effective in preventing growth of both lymphoid and solid tumors in vivo, and Thy I+ cells were essential for the anti-tumor effect. The ability to generate LICC was preserved in the tumor-bearing hosts until the terminal stage of tumor growth, when the generation of suppressor T-cells interfered with LICC induction. LICC seem to play an important role in defense against non-immunogenic tumors.

Animals↗

Lymphokine-induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic response.

Lymphokines induce the generation of cytotoxic cells (LICC) in the absence of antigenic or mitogenic stimulation. In the present study, we have demonstrated that at least two lymphokines are involved. They are interleukin 2-conditioned medium (CM-IL 2), which was produced by W/Fu rat spleen cells cultured with concanavalin A-conjugated Sepharose beads, and cytotoxic cell differentiation factor-conditioned medium (CM-CCDF), which was produced primarily by the unstimulated mouse peritoneal macrophages. It was first established that CCDF synergized with IL 2 to induce the generation of LICC in normal spleen cells, and that this process was specifically blocked by the rat anti-IL 2 receptor monoclonal antibody. The maximal synergistic effect was obtained by using 10% CM-CCDF (v/v) and 0.1 to 0.3 U/ml of CM-IL 2. Higher doses of IL 2 (3 to 10 U/ml) reduced the cytotoxic response. The effectors of LICC were Thy-1+, Lyt-2- and AGM1-; therefore, they were neither classic CTL nor NK cells. The precursors were AGM1+, Lyt-2- cells that were consistent of being NK-like cells. When examining the temporal relationship between CCDF and IL 2, we found that 4 hr preincubation of the responders with IL 2 was sufficient to activate the cytotoxic precursor cells. CCDF was needed later for the differentiation of the activated precursors into cytotoxic effectors. In contrast, preincubation of the responders with CCDF, followed by additional incubation with IL 2, failed to induce any cytotoxic response. These results established that lymphokine-induced cytotoxicity can be separated into two phases. In the activation phase, IL 2 provides the first signal to activate the cytotoxic precursors, with the process being completed in 4 hr. In the differentiation phase, CCDF provides the second signal to induce the differentiation of the IL 2-activated precursors into cytotoxic effectors, with this process requiring 48 hr to complete. The sequential presence of these lymphokines at an appropriate time during the activation and differentiation phases is critical for the generation of LICC response.

Animals↗

Regulation of the activation of cytotoxic T lymphocytes by prostaglandins and antigens.

The present study demonstrated the presence of two suppressor circuits in the regulation of the in vitro activation and differentiation of cytotoxic T lymphocytes (CTL); these suppressor circuits were mediated by prostaglandins (PG) and antigens, respectively. In intrinsic suppression, the activation of cytotoxic precursor cells was regulated by the host endogenous production of PG. When the regulation by PG was removed (e.g., using indomethacin), lymphokine-induced cytotoxic cells (LICC) were generated. This activation process can be induced in the absence of antigen or mitogen stimulation. In extrinsic suppression, the presence of antigen induced the generation of antigen-nonspecific suppressor T cells to restrict the expansion of antigen-unrelated cytotoxic lymphocyte clones, whereas the antigen-specific CTL clones were spared. The generation of antigen-specific helper cells further augmented the antigen-specific CTL response. These findings indicate that both antigen specific suppressor T cells and antigen nonspecific suppressor T cells are involved in the regulation of CTL responses. These suppressor circuits not only play an active role in monitoring the activation of CTL clones, they also help to determine the specificity and magnitude of the CTL response.

Animals↗

Induction of suppressor T cells by interleukin 2.

The optimal concentration of interleukin 2 (IL 2) for maintaining the in vitro growth of T cells was quite different from that required for the induction of cytotoxic T lymphocytes (CTL) in nu/nu spleen cells. Higher concentrations of IL 2-containing preparations (10 to 30% v/v or 5 to 15 U/ml) were needed to promote the T cell growth, whereas lower concentrations (1 to 3% v/v or 0.5 to 1.5 U/ml) were needed to generate alloreactive CTL. It was further shown that the addition of high concentrations of IL 2 (10 to 30%) suppressed the generation of alloreactive CTL in conventional MLC. High concentrations of IL 2 induced the generation of antigen-nonspecific suppressor T cells in normal spleen cell cultures and augmented the generation of antigen-specific suppressor T cells in MLC. These suppressor cells suppressed the generation of CTL in fresh MLC and in polyclonal CTL cultures. These suppressor T cells could be induced by rat (spleen)-produced, murine (EL-4 cells) produced IL 2 preparations, and a purified human recombinant IL 2 (HR-IL2). The ability to induce suppressor cells correlated with the activity of IL 2 present in these preparations and was independent of their ability to induce cytotoxic effectors. These findings indicate that IL 2 may play a dual role in the regulation of CTL responses. We suggest that during antigen sensitization, the initial endogenous production of lower levels of IL 2 provided the second signal for the differentiation and proliferation of CTL. When higher levels of IL 2 were produced later, the suppressor T cell precursors were activated and differentiated into suppressor effectors to regulate the CTL response.

Animals↗

Studies of the mechanisms for the induction of in vivo tumor immunity. VII. Development of specific antitumor immunity in progressors and regressors.

The present study was aimed at comparing the development of specific antitumor immunity between hosts with progressively growing tumors and hosts with regressing tumors. The experiments were performed with a Friend virus-induced leukemia FBL-3 in syngeneic C57BL/6 mice. The specific antitumor immunity was determined by in vitro cell-mediated cytotoxicity assay and in vivo tumor neutralization test. Both the systemic immunity (demonstrated in spleen) and immunity developed at tumor site were examined. For progressors, the tumor site was in the peritoneal cavity. For regressors, it was in a subcutaneous site of both flanks. Testing by the cell-mediated cytotoxicity assay showed that immune hosts and regressors had higher levels of systemic immunity than the progressors. However, when lymphocytes isolated from tumor sites were assayed, it was found that there was no remarkable difference between lymphocytes from progressor tumors (PTL) and lymphocytes from regressor tumors (RTL). Both lymphocyte populations were similar in profile analysis; they were characterized as T cells and possessed the same antigenic specificity. Nevertheless, when in vivo tumor transplantation experiments were performed, RTL were found to give protection against FBL-3 challenge whereas PTL consistently failed to do so. On cytomorphological examination, the PTL were seen to contain large amounts of macrophages. The presence of macrophages in PTL appeared to have an inverse relationship to the in vivo protective effect. After removal of macrophages from PTL by Petri dish adherence, the nonadherent PTL were found to give in vivo protection. Furthermore, thymocytes from progressors and macrophages isolated from the progressor tumors were found to suppress the in vivo T-cell-mediated immunity. These findings demonstrated that suppressor T cells and suppressor macrophages were present in tumor-bearing hosts. These suppressor cells could interfere with the function of immune T cells at the efferent arm of the immune response.

Animals↗

Activation of natural killer-derived cytotoxic T lymphocytes. I. Regulation by macrophage and prostaglandins.

The present study describes a mechanism that regulates the activation of cytotoxic T lymphocytes (CTL) derived from natural killer (NK) cells. In the absence of antigenic stimulation, polyclonal activation of cytotoxic lymphocytes was induced by culturing the splenic responders with exogenous peritoneal macrophages and indomethacin. The effectors were characterized as T cells, whereas the precursors were of NK origin. To activate these NK-derived CTL, although there was no need for direct contact between responding precursors and macrophages, the role of macrophages could not be substituted by the addition of exogenous IL 2, macrophage supernatant, or IL 1. In contrast, supernatant from syngeneic lymphocyte-macrophage cultures with indomethacin induced CTL generation. This finding indicates that other lymphokines might also be produced and that they are essential for CTL activation. The need for indomethacin, a prostaglandin (PG) synthetase inhibitor, indicated that PG also played a regulatory role. The addition of 1 X 10(-9) M to 1 X 10(-8) M exogenous PGE2 to the cultures in the first 24 to 48 hr completely suppressed CTL activation. Our results clearly show that through regulation by macrophages and PG, NK-derived precursors differentiated into mature CTL. A different receptor repertoire appeared to be present in different clones of NK precursors. In the absence of antigenic stimulation, removal of the restriction by PG allowed the macrophages or their products to interact with the lymphocyte to produce various lymphokines. These lymphokines further signaled the NK precursors to be polyclonally activated and to differentiate into CTL.

Animals↗

Effect of interleukin 2 on cytotoxic effectors: I. Short-term culture of the cytotoxic effectors and the in vivo anti-tumor activity of the cultured effectors isolated from tumor site.

The effects of interleukin 2 (IL2) on the in vitro and in vivo activity of cytotoxic T cells have been studied. IL2 was produced by W/Fu rat spleen cells cultured with concanavalin A. The IL2 thus prepared gave an optimal T-cell growth-promoting effect at a concentration of 5-20% equivalents of the original preparation. In the primary syngeneic mixed lymphocyte/tumor cell cultures (MLTC) against FBL-3 tumor cells, the addition of IL2 failed to generate a cytotoxic response. However, the cytotoxic response could be generated in MLTC by addition of exogenous macrophages. On the other hand, IL2 could maintain the growth of performed cytotoxic T cells for 3 to 5 weeks. These cytotoxic T cells were generated either by in vitro sensitization (MLC or MLTC) or by in vivo sensitization of B6 mice against a syngeneic tumor FBL-3. In short-term cultures, augmentation of the cytotoxic activity was seen after 10 days' culturing with IL2. The antigenic specificity of the cytotoxic reaction was altered after 28-35 days in culture, and the effectors broadly reactive. When growing a nonadherent population of lymphocytes isolated from FBL-3 ascites tumor, supplementation with IL2 selectively promoted the growth of a T-cell population, resulting in the elimination of the contaminating tumor cells. These purified T cells were highly cytotoxic for FBL-3 cells in vitro and also possessed strong in vivo anti-tumor activity against FBL-3 cells in the adoptive transfer experiments. The present study demonstrates that short-term culture (2-3 weeks) in IL2 promotes the growth of T cells and augments their cytotoxic activity with the appropriate antigenic specificity. IL2 also promoted the selective growth of T cells isolated from tumor site and these T cells showed augmented in vitro and in vivo anti-tumor activity.

Animals↗